Prolific Machines, a biotechnology company revolutionizing biologics manufacturing, announced today that it has been accepted ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Discover upcoming breakthroughs in Type 1 Diabetes & B-cell disorder treatments, market growth to $24B by 2031, and key ...

Supreme Court upholds lower court's decision that SK bioscience's PCV13 components do not fall within scope of Pfizer's patent claims - Anadolu Ajansı ...

CRISPR-edited iPSCs uncover early mitochondrial defects shared across ALS mutations, revealing pathways that could guide future treatments.

The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

The company, which was founded in 2006, rose to prominence by offering at-home DNA testing kits that allowed people to ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Franklin Biotechnology Discovery Fund's Q1 2025 report covers market trends, key holdings, risks, and outlook—essential ...

The grant would have used artificial intelligence to shorten drug development and provide affordable drugs, vaccines and diagnostics.

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.